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The HIV reverse-transcriptase inhibitor, tenofovir,
was recently formulated into a vaginal gel for use
as a microbicide. In human trials, a 1% tenofovir gel
inhibited HIV sexual transmission by 39% and,
surprisingly, herpes simplex virus-2 (HSV-2) trans-
mission by 51%. We demonstrate that the concen-
tration achieved intravaginally with a 1% tenofovir
topical gel has direct antiherpetic activity. Tenofovir
inhibits the replication of HSV clinical isolates in
human embryonic fibroblasts, keratinocytes, and or-
ganotypic epithelial 3D rafts, decreases HSV replica-
tion in human lymphoid and cervicovaginal tissues
ex vivo, and delays HSV-induced lesions and death
in topically treated HSV-infected mice. The active te-
nofovir metabolite inhibits HSVDNA-polymerase and
HIV reverse-transcriptase. To exert dual antiviral
effects, tenofovir requires topical administration to
achieve a drug concentration higher than systemic
levels achievedbyoral treatment. Thesefindings indi-
cate that a single topical treatment, like tenofovir, can
inhibit the transmission of HIV and its copathogens.
INTRODUCTION
Unprotected heterosexual intercourse remains a major trans-
mission mode of HIV-1. In the absence of a protective vaccine,
an efficient topical vaginal microbicide would be critical to the
prevention of male-to-female HIV-1 transmission and to curbing
the worldwide AIDS epidemic (Balzarini and Van Damme, 2007;
Klasse et al., 2008). HIV-1 infection is commonly associated with
other sexual infections, such as HSV, that facilitate the risk of
HIV acquisition and worsen the clinical course of HIV disease
(Blower and Ma, 2004; Corey, 2007; Buve´, 2010). Therefore, it
would be beneficial if a future microbicide was efficient not
only against HIV-1, but also against other sexually transmitted
infections.Cell HostUnfortunately, until recently, all microbicide formulations that
successfully passed preclinical testing failed to demonstrate effi-
ciency in the early stages of clinical development (Van Damme
et al., 2002, 2008; Abdool Karim, 2010), and some of them
apparently promoted HIV-1 infection (Van Damme et al., 2002,
2008).
Instead of testing new compounds as potential microbi-
cides, tenofovir, an efficient nucleotide HIV reverse-transcrip-
tase (RT) inhibitor (Balzarini et al., 1993) widely used in HIV
therapy, was recently formulated as a 1% gel and tested in
a double-blind placebo-controlled study in 889 women
(CAPRISA 004 [Abdool Karim et al., 2010]). Tenofovir convinc-
ingly diminished HIV-1 transmission (by 39%). Surprisingly, in
the CAPRISA 004 trial, a significant 51% reduction of the
risk of acquiring HSV-2, a common HIV-1 copathogen that
facilitates HIV transmission, was also observed (Cates, 2010).
This effect of tenofovir gel on HSV was rather unanticipated
because this highly potent antiretroviral and antihepadnaviral
drug has been previously shown to exhibit minimal, if any,
anti-HSV activity (Balzarini et al., 1993). Therefore, one might
have envisioned a complicated and indirect mechanism to
explain this phenomenon. It turned out not to be the case.
In the present study, we report on the resolution of this
apparent contradiction. We provide compelling evidence that,
at the concentrations achieved intravaginally by the topical
administration of a 1% gel, tenofovir exhibits direct antiherpetic
activity. These data and the therapeutic principles emerging
from our study are important for the development of new drug
formulations and administration protocols to design and/or opti-
mize future microbicide trials.RESULTS
Tenofovir Inhibits HSV-1 and HSV-2 Replication
in Various Cell Cultures
Tenofovir inhibited cytopathicity of the laboratory strains of
HSV-1 and HSV-2 in human embryonic lung (HEL) fibroblasts
and in primary human keratinocytes (PHKs) with EC50 values
of 103–193 mg/ml (Table 1). In HEL fibroblasts, tenofovir
consistently inhibited the cytopathic effects of a variety of& Microbe 10, 379–389, October 20, 2011 ª2011 Elsevier Inc. 379
Table 1. Antiviral Activity againstWild-Type andAcyclovir-Resistant Laboratory Strains andClinical Isolates ofHSV-1 andHSV-2Using
the CPE Reduction Assay
Cell Type Viral Strain
EC50
a (mg/ml)
Acyclovir Tenofovir Adefovir Cidofovir
HSV-1 Laboratory Strain
HEL Kos 0.053 ± 0.046 132 ± 20 6.0 ± 3.5 0.63 ± 0.36
PHKs Kos 0.42 ± 0.15 141 ± 53 9.2 ± 0.1 1.4 ± 0.03
HSV-2 Laboratory Strain
HEL G 0.10 ± 0.10 103 ± 31 3.6 ± 0.1 0.70 ± 0.37
PHKs G 0.45 ± 0.07 193 ± 17 13.0 ± 2.1 4.4 ± 2.8
HSV-1 Wild-Type Clinical Isolates
HEL RV-132 0.031 ± 0.005 114 ± 8 6.7 ± 2.4 0.90 ± 0.15
RV-134 0.063 ± 0.040 160 ± 57 10.2 ± 2.5 1.19 ± 0.57
RV-6 0.075 ± 0.040 131 ± 29 4.3 ± 0 0.36 ± 0.01
C559142 0.018 ± 0.012 101 ± 14 3.6 ± 0.8 0.22 ± 0.17
RV-174 0.039 ± 0.002 110 ± 0 5.8 ± 1.1 0.43 ± 0.11
RV-175 0.018 ± 0.020 109 ± 2 5.0 ± 0 0.82 ± 0.30
HSV-1 TK Clinical Isolatesb
HEL RV-117 (stop codon at position R281) 22.6 ± 4 R159 ± 48 6.4 ± 3.0 0.36 ± 0.18
328058 (Nts 548-553, C deletion in a string of 6Cs) >20 ± 0 117 ± 25 3.1 ± 0.9 0.13 ± 0.01
RV-36 (substitution T245M) R20 ± 0 179 ± 29 6.0 ± 5.7 0.42 ± 0.30
RV-179 (Nts 430-436, G insertion in a string of 7Gs) 10 ± 5 100 ± 0 3.2 ± 0.7 0.14 ± 0.01
HSV-2 Wild-Type Clinical Isolates
HEL RV-124 0.086 ± 0.021 163 ± 52 7.3 ± 0.9 0.90 ± 0.15
RV-24 0.12 ± 0.02 125 ± 22 7.5 ± 1.7 1.07 ± 1.11
NA 0.045 ± 0.032 R134 ± 76 3.4 ± 1.2 0.32 ± 0.26
PB 0.11 ± 0.03 176 ± 34 5.2 ± 3.2 0.60 ± 0.39
NS 0.05 ± 0 147 ± 7 3.0 ± 1.4 0.53 ± 0.18
HSV-47 0.037 ± 0.004 176 ± 34 5.4 ± 4.2 0.62 ± 0.54
HSV-2 TK Clinical Isolatesb
HEL RV-129 (Nts 433-439, G insertion in a string of 7Gs) R20 ± 0 163 ± 52 7.5 ± 3.5 0.49 ± 0.24
BA 19026589 (Nts 792-796, G deletion in a string of 5 Gs) 7.5 ± 3.5 179 ± 29 10.0 ± 0 1.43 ± 0
LU C557672 (Nts 808-811, C insertion in a string of 4Cs >20 ± 0 131 ± 6 7.5 ± 3.5 0.50 ± 0
RV-101 (Nts 551-556, C insertion in a string of 6Cs) >20 ± 0 144 ± 80 5.1 ± 2.6 0.33 ± 0.16
HSV-44 (Nts 433-439, G deletion in a string of 7Gs) >20 ± 0 142 ± 82 6.0 ± 5.7 0.35 ± 0.40
RV-184 (Nts 551-556, C deletion in a string of 6Cs) 12 ± 3 87 ± 18 3.3 ± 0.6 0.35 ± 0.04
RV-185 (Nts 433-439, G insertion in a string of 7Gs) 21 ± 9 85 ± 8 4.1 ± 1.3 0.32 ± 0.07
Cell Type
Cell Toxicity (mg/ml)
Acyclovir Tenofovir Adefovir Cidofovir
CC50
c MCCd CC50 MCC CC50 MCC CC50 MCC
HEL 166 ±17 >100 547 ± 39 >400 100 ± 57 >100 82 ± 57 >100
PHKs 132 >50 >50 >200 17 ± 6 >50 34 ± 20 >50
Confluent HEL and PHK cell cultures were exposed to 100 TCID50 of virus in the presence of different drug concentrations and incubated for 3 days at
37C. Then, the cytopathicity was determinedmicroscopically and the EC50 values determined. Cell toxicity (CC50 andMCC) was measured in parallel
in noninfected cell cultures.
a EC50, 50% effective concentration or compound concentration required to reduce virus-induced cytopathicity (CPE) by 50%. Data shown are the
mean values (±SD) of at least two independent experiments.
b Nucleotide position refers to the coding region of the TK gene.
c CC50, 50% cytostatic concentration or compound concentration required to reduce cell growth by 50%.
dMCC, minimum cytotoxic concentration that causes a microscopically detectable alteration of cell morphology.
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Direct Antiherpetic Activity of Tenofovirwild-type HSV-1, thymidine kinase-deficient (TK) HSV-1, wild-
type HSV-2, and HSV-2 TK clinical isolates with mean EC50
values of 123 mg/ml (range of 101–160 mg/ml), R 139 mg/ml380 Cell Host & Microbe 10, 379–389, October 20, 2011 ª2011 Elsev(100 to R 159 mg/ml), 154 mg/ml (125–176 mg/ml), and
133 mg/ml (85–179 mg/ml), respectively. The antiherpesvi-
rus activity of tenofovir was revealed at a concentration rangeier Inc.
Figure 1. InhibitoryActivityof Tenofovir againstHSV-2ReplicationCytopathicity inHELCellCulturesUsingDifferentMultiplicities of Infection
Virus yield was determined at 24, 48, and 72 hr postinfection, and EC90 and EC99 values were calculated from the graphical plots. Error bars represent ± SD.
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Direct Antiherpetic Activity of Tenofovirthat is markedly higher than those established for antiherpetic
drugs, such as acyclovir and its closely related acyclic
nucleoside phosphonate congeners, adefovir and cidofovir
(Table 1).
There was no marked difference in the suppression of HSV-1
and HSV-2 replication by tenofovir and the reference antiher-
pesvirus agents. Importantly, there were no signs of tenofovir
cytotoxicity, as assessed from HEL cell morphology, even at
the highest drug concentrations used (500 mg/ml). The effects
of tenofovir on HSV-2 yield in HEL cells were also determined
at 24, 48, and 72 hr postinfection to confirm the data obtained
using the cytopathic effect (CPE) reduction assay. The dose-
response curves of tenofovir for two clinical HSV-2 isolates
(RV-124 and NS) at two different multiplicities of infection
(moi) were determined using the plaque-forming unit (PFU)
reduction assay and are depicted in Figure 1. Tenofovir in-
hibited the replication of both viruses with EC99 values (i.e.,
the drug concentration that decreases the virus titers by two
orders of magnitude) in the range of 214–390 mg/ml, whereas
no changes in cell number were noted at any drug
concentration.
The effect of tenofovir was also evaluated against HSV-2 in
primary monocyte/macrophage (M/M) cell cultures using two
different methods, CPE reduction and PFU reduction assays.
Tenofovir dosage of 500 or 100 mg/ml completely suppressed
HSV-2 replication in M/M. HSV-2 production dropped from
3.7 3 105 TCID50/ml (95% cytopathicity) in the culture super-
natants of untreated cells by more than one log10 in 20 mg/ml
and an approximate half log10 in 5 mg/ml tenofovir-treated
cultures. At 1 mg/ml or 0.2 mg/ml drug concentrations, no signif-
icant protective effect of tenofovir was observed (2.4–3.0 3 105Cell HostTCID50/ml; 66%–81% cytopathicity) (Table 2 and Figure S1
available online). As expected, the structurally related reference
compound adefovir, which was included as a control in the
assay, proved to be more potent in its anti-HSV-2 activity in
the M/M cell cultures (full CPE suppression at 5 mg/ml) than te-
nofovir (Table 2).
Tenofovir Suppresses Viral Replication in Organotypic
Epithelial Raft Cultures
Because differentiated keratinocytes are themain target cells for
productive infection of HSV in vivo, we evaluated the antiviral
activity of tenofovir in organotypic raft cultures of keratinocytes.
The organotypic epithelial raft cultures were infected after
10 days of differentiation and treated with tenofovir. After
5 days of drug treatment, histological examination of the nonin-
fected raft cultures revealed completely differentiated epithelium
with characteristic layers, whereas HSV-infected rafts revealed
a pronounced viral infection that had spread all along the epithe-
lium (Figure 2). At a concentration of 200 mg/ml, tenofovir caused
a 2.6 (HSV-1) and a 5.4 (HSV-2) log10 reduction in virus produc-
tion and complete protection of virus-induced cytopathicity
(Figure 3). A 0.81 (HSV-1) and a 1.75 (HSV-2) log10 reduction
was recorded at a concentration of 50 mg/ml of tenofovir. At 20
and 5 mg/ml, tenofovir was partially protective, with areas of
a normal epithelium and areas of destructed rafts. At a concen-
tration of 2 mg/ml, tenofovir was inactive against HSV-2 (Figure 3).
The higher activity of tenofovir against HSV-2, but not HSV-1,
can be due to the different levels of replication between these
two viruses: in the untreated control cultures, the HSV-2
titers were lower (1.5 3 106 PFU/raft) than the HSV-1 titers
(9 3 106 PFU/raft).& Microbe 10, 379–389, October 20, 2011 ª2011 Elsevier Inc. 381
Table 2. Inhibitory Activity of Tenofovir and Adefovir against HSV-2 in Primary Monocyte/Macrophage Cultures Using the CPE
Reduction Assay and the PFU Reduction Assay
Treatment
Virus Production
(TCID50/ml)
Inhibition of Virus
Production (% of Control)
CPE Reduction Assay
Virus Production
(PFU/ml)
Inhibition of Virus
Production (% of Control)
PFU Reduction Assay
Cytopathicity
(CPE) (%)
None 3.7 3 105 9 3 104 95
Tenofovir (mg/ml)
500 No virus 100 No virus 100 None
100 No virus 100 No virus 100 None
20 1.3 3 104 96 2.2 3 103 98 5
5 7.2 3 104 80 1.9 3 104 79 60
1 2.4 3 105 34 6.6 3 104 27 70
0.2 3 3 105 19 7.3 3 104 19 80
0.04 3.2 3 105 13 8.5 3 104 6 85
Adefovir (mg/ml)
500 No virus 100 No virus 100 None
100 No virus 100 No virus 100 None
20 No virus 100 No virus 100 None
5 No virus 100 No virus 100 None
1 8 3 102 99 2.5 3 102 99 None
0.2 6 3 104 84 9.9 3 103 89 5
0.04 1 3 105 73 1.8 3 104 80 40
Virus production was evaluated on day 6 postinfection. HSV-2was quantified in the supernatants of drug-treated virus-infected cell cultures by titration
in Vero cell cultures using the CPE reduction assay (calculation of TCID50/ml) and the PFU reduction assay (calculation of PFU/ml). See also Figure S1.
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Direct Antiherpetic Activity of TenofovirTenofovir Suppresses HSV-2 in Singly Infected and in
HIV-1-Coinfected Human Lymphoid and Cervicovaginal
Tissue Ex Vivo
The effect of tenofovir on the replication of HSV-1F, HSV-2G, and
HSV-2MS was investigated in infected human tonsillar tissues
ex vivo (Figure 4). Upon inoculation in human tonsillar tissues
ex vivo, HSV-1F, HSV-2G, or HSV-2MS replicated efficiently, as
shown by accumulation of viral DNA in culture medium. The
median accumulation throughout the 9 days of culture was
7.8 log10 DNA copies/ml (interquartile range [IQR] 7.1–8.1,
n = 5); 7.25 log10 DNA copies/ml (IQR 7.2–7.9, n = 6); and 6.4
log10 DNA copies/ml (IQR 6.1–7.5, n = 3) for HSV-1F, HSV-2G,
and HSV-2MS, respectively.
Tenofovir suppressed replication of HSV-1F, HSV-2G, and
HSV-2MS in a dose-dependent manner (Figure 4). On the basis
of the real-time PCR data presented above, we calculated the
EC50 for HSV suppression of tenofovir as 7 mg/ml (95% confi-
dence interval [CI] 10–44) for HSV-1F; 14 mg/ml (CI 10–163) for
HSV-2G (Figure 4A); and 19 mg/ml (CI 27–127) for HSV-2MS. The
EC50 calculated by this technique is in agreement with that ob-
tainedwith thePFU reductionassay (Thi et al., 2006). Accordingly,
tenofovir at a concentration of 66 mg/ml reduced HSV-1F,
HSV-2G, and HSV-2MS replication by 99% ± 0.1%, 87% ± 12%,
and 91.7% ± 3.2%, respectively, compared to infected donor-
matched untreated tissue (p < 0.01). At the 66 mg/ml tenofovir
concentration, thesuppressionofHSV-1F,HSV-2G, andHSV-2MS
replication was not associated with measurable tonsillar deple-
tion of either total T cells (CD3+), total B cells (CD19+), or subsets
of naive and memory T cells compared to donor-matched
untreated tissues (n = 3, p > 0.4), in which the loss of these cells
between days 1 and 12 in culture was negligible (Grivel et al.,382 Cell Host & Microbe 10, 379–389, October 20, 2011 ª2011 Elsev2000). In tonsillar tissues coinfected with HSV-2G and HIV-1LAI,
66 mg/ml tenofovir (maintained throughout the entire culture
period) inhibited replication of both viruses: in the untreated
control tissues, HSV-2G DNA release into culture medium was
7.3 log10DNAcopies/ml (IQR6.8–7.4),whereas indonor-matched
tissues treated with 66 mg/ml tenofovir HSV-2G, replication was
suppressed by 96% ± 1% (n = 6; p < 0.01). In these tissues,
HIV-1LAI was inhibited completely (Figure 4B). The antiherpetic
effect of tenofovir is not a general property of the nucleoside
reverse-transcriptase inhibitors (NRTIs) as we found no effect of
lamivudine (3TC) on HSV-2G replication (data not shown). Finally,
we found no effect of tenofovir (at 66 mg/ml) on the release of 15
cytokines (IL-1a, IL-6, IL-8, IL-15, IL-16, CCL3/MIP-1a, CCL4/
MIP-1b, CCL20/MIP-3a, CCL5/RANTES, CXCL12/SDF-1b,
CCL2/MCP-1, CCL11/Eotaxin, CXCL9/MIG, CXCL10/IP-10, and
GM-CSF) into the culture medium (p > 0.15). Tenofovir at
a concentration of 150 mg/ml also inhibited HSV-2G replication in
cervicovaginal tissue ex vivo from 6.6 log10 DNA copies/ml (IQR
5.3–8.2) to 5.5 log10 DNA copies/ml (IQR 4.8–5.7, n = 5) (Figures
4C and 4D), reflecting 78% ± 9% reduction when the reductions
of viral replication in each experiment were averaged (p < 0.01).
Activity of Tenofovir in HSV-Infected Mice
The anti-HSV-1- andHSV-2 activities of tenofovir were evaluated
in virus-infected athymic nude mice (lumbosacral scarification
model). The drug was administered to HSV-1- and HSV-2-in-
fected mice at a concentration of 1% in DMSO for 5 days, start-
ing at the day of infection. Mice treated with placebo (DMSO)
developed lesions in the lumbosacral area, leading to paralysis
of the hind legs and, finally, death. Treatment with tenofovir
(1%) resulted in a statistically significant delay of morbidity andier Inc.
Figure 2. Effects of Tenofovir on Organotypic Epithelial Rafts Cultures Infected with HSV-2G at 10 Days after Lifting
Compounds were added to the culture media on the day of infection and remained in contact with the cells until the rafts were fixed (i.e., at 15 days after lifting).
Magnification, 403.
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Direct Antiherpetic Activity of Tenofovirprolonged the survival of the mice infected with HSV (Figure 5A).
Tenofovir was somewhat more active against HSV-1 than HSV-
2, for unknown reasons. Also, when formulated in a 1% gel (as
used in the CAPRISA 004 microbicide trial), tenofovir signifi-
cantly (p < 0.01) delayed the appearance of herpesvirus-relatedFigure 3. Quantification of Virus Yield in Organotypic Epithelial Raft Cu
Cultures
Compounds were added to the culture media on the day of infection (i.e., 10 days
until the rafts were frozen for determination of virus production by a plaque assay
virus production to take into account the variation of epithelial thickness among
Cell Hostlesions and subsequent death of the animals compared to
placebo (same gel formulationwithout drug) (Figure 5B). Adefovir
performed markedly better against HSV-1 than HSV-2 in the 1%
gel-treated mice, but was virtually not superior to tenofovir
against HSV-2 (Figure 5B).ltures Infected with HSV-1 or HSV-2 at Day 10 after Initiation of Cell
after initiating differentiation) and remained in contact with the cells for 5 days
in HEL cell cultures. Two independent rafts were used for the quantification of
the rafts. Error bars represent ± SD.
& Microbe 10, 379–389, October 20, 2011 ª2011 Elsevier Inc. 383
Figure 4. Suppression of HSV-2 in Singly Infected and HIV-1-Coinfected Human Ex Vivo Lymphoid Tissue by Tenofovir
(A) Blocks of human tonsillar tissue were inoculated ex vivo with HSV-2G and treated or not treated with tenofovir (3, 15, 66, or 240 mg/ml). HSV-2G replication was
monitored by measuring viral DNA in culture media (day 9 postinfection). Presented are means ± SEM of the results with tissues from 14 donors. For each donor,
each data point represents pooled viral release from 27 tissue blocks.
(B) Blocks of human tonsillar tissue were coinoculated ex vivo with HSV-2G and HIV-1LAI and treated or not treated with tenofovir (66 mg/ml). HIV-1 replication was
monitored by measuring p24gag accumulated in culture media over 3 day periods. Presented are means ± SEM of the results with tissues from six donors. For
each donor, each data point represents pooled viral release from 27 tissue blocks.
(C) Blocks of human cervicovaginal tissues were inoculated ex vivo with HSV-2G and treated or not treated with tenofovir (150 mg/ml). HSV-2G replication was
monitored by measuring viral DNA accumulated in culture media at different time points throughout the culture period. Presented is a representative experiment
(out of five) with a tissue from an individual donor. Each data point represents pooled viral release from 16 tissue blocks.
(D) Blocks of human cervicovaginal tissues were inoculated ex vivo with HSV-2G and treated or not treated with tenofovir (150 mg/ml). HSV-2G replication was
monitored by measuring viral DNA accumulated in culture media at different time points throughout the culture period. Presented are means ± SEM of the results
with tissues from five donors. For each donor, each data point represents pooled viral release from 16 tissue blocks.
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Direct Antiherpetic Activity of TenofovirTenofovir Is Converted to Its Antivirally Active
Metabolite in Relevant Cell Cultures
In lymphocytic CEM, epithelial TZM-Bl, and fibroblast HEL
cultures, [2,8-3H]tenofovir (0.60 mg/ml, applied for 24 hr starting
from 72 hr postinitiation of the cultures) was converted into teno-
fovir-diphosphate. Concentrations of this metabolite reached
5.4 ± 0.6, 5.2 ± 2.2, and 19 ± 17 ng/109 cells in lymphocytic cells,
epithelial cells, and fibroblasts, respectively. We also demon-
strated that, at increasing tenofovir concentrations (i.e., 0.6, 6,
60, or 600 mg/ml), concomitantly higher tenofovir diphosphate
concentrations were formed (5.18 ± 2.2, 103 ± 15.2, 1,026 ±
103, and 10,400 ± 800 ng/109 TZM-Bl cells, respectively).
Thus, epithelial cells exposed to 600 mg/ml tenofovir concentra-
tions produced as much as 10.4 ± 0.8 ng of tenofovir diphos-
phate/106 cells (this corresponds to an 3 mg/ml if we consider
a cell volume to be 4 pl (Alberts et al., 1994)) without any sign
of toxicity, as measured upon microscopic inspection. Also,
MTT dye viability testing of epithelial cell cultures that were384 Cell Host & Microbe 10, 379–389, October 20, 2011 ª2011 Elsevexposed to up to 1,000 mg/ml tenofovir did not showmeasurable
toxicity (data not shown). Such a linear relationship between
external tenofovir concentrations and intracellular tenofovir
diphosphate concentrations has been observed earlier (Balzarini
et al., 1991). This characteristic of tenofovir allows sufficiently
high HSV-2-suppressive levels of tenofovir diphosphate metab-
olite upon application of 1% tenofovir (10 mg/ml) gel. Thus, teno-
fovir is efficiently converted to its antivirally active metabolite in
multiple different cell types that represent relevant target cells
for either HIV or HSV infection in vivo.
The Active Metabolite of Tenofovir Efficiently Inhibits
Both HSV DNA Polymerase and HIV Reverse-
Transcriptase
The active tenofovir metabolite, tenofovir diphosphate, has
been evaluated for its inhibitory activity against the HIV-1
reverse-transcriptase and HSV DNA polymerase using activated
calf thymus DNA as the primer/template and [2,8-3H]ier Inc.
Figure 5. Effect of Tenofovir, Adefovir, andCidofovir Treatment in DMSOFormulation or in Gel Identical to that Used in the CAPRISA 004 Trial
on Development of Lesions and Mortality in Mice Inoculated with HSV-1 or HSV-2
(A and B) Groups of five nu/nu mice were inoculated with HSV-1 or HSV-2 on the lumbosacral area. Each cohort was then subjected to topical treatment twice
daily for 5 consecutive days, starting the day of viral infection. The placebo groups received a similar treatment with the test formulation without drug. Devel-
opment of skin lesions, paralysis, and mortality were recorded over a period of 20 days. Animals were euthanized when more than 30% loss in body weight or
development of paralysis occurred. Survival rateswere estimated according to the Kaplan-Meiermethod andwere compared using the log-rank test (Mantel-Cox
using GraphPad Prism).* p < 0.05; ** p < 0.01.
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Direct Antiherpetic Activity of Tenofovir20-deoxyadenosine triphosphate (dATP) as the competing
substrate. Tenofovir diphosphate efficiently inhibited HIV-1 RT
with an IC50 of 1.3 mg/ml in the presence of dATP (3.2 mM) as
the competing deoxynucleotide triphosphate (dNTP). Tenofovir
diphosphate also inhibited herpesvirus DNA polymerase-
catalyzed polymerization at IC50s of 0.38 ± 0.03 mg/ml, 7.1 ±
5 mg/ml, 8.5 ± 3.8 mg/ml, and 25 ± 1.8 mg/ml in the presence ofCell Hostcompeting dATP (3.2 mM), dGTP (2.8 mM), dTTP (1 mM), or
dCTP (2.5 mM), respectively.
Thus, the antiherpetic activity of tenofovir in cell cultures, orga-
notypic epithelial raft cultures, human lymphoid and cervicovagi-
nal ex vivo tissues, and virus-infectedmice can be fully explained
by the inhibition of the viral DNA polymerase by its active metab-
olite, tenofovir diphosphate.& Microbe 10, 379–389, October 20, 2011 ª2011 Elsevier Inc. 385
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Tenofovir is a common anti-HIV drug that, in the currently
approved dose (300 mg tablet), suppresses HIV-1 replication
in vivo and in vitro but is not reported to markedly affect herpes
viruses (Balzarini et al., 1993). Recently, however, it was reported
that, in themicrobicide CAPRISA 004 trial, topical vaginal admin-
istration of tenofovir significantly diminished the acquisition not
only of HIV-1, but also of HSV-2. We hypothesized that the
discrepancy between the earlier reported lack of significant anti-
herpetic activity and the CAPRISA 004 data is explained by the
striking differences in drug concentrations between systemic
and topical applications of tenofovir.
We demonstrated that the antiretroviral drug tenofovir is
indeed endowed with a direct antiherpetic activity in a variety of
experimental models at drug concentrations that are lower than
the median concentration achieved in cervicovaginal fluid
following the administration of 1% tenofovir gel and that were
nontoxic for the exposed cells (Rohan et al., 2010 and data of
this study). Indeed, tenofovir levels in the cervicovaginal fluid
were reported as 18.6 mg/ml.hr, measured over a 24 hr time
period (AUC24hr) after topical administration, and levels were still
at 100 mg/ml at 24 hr after drug exposure (Schwartz et al.,
Abstract LBPEC03, 5th IAS, Cape Town, South Africa, 19-22
July 2009). Rather, it was shown by Dumond et al. (2007) that
the steady-state genital concentration of tenofovir was
100 ng/ml (24 hr), andpeak concentrations of tenofovir reached
500 ng/ml (6 hr) after administration of tenofovir by oral route.
Several recent publications report lower concentrations of
tenofovir in the female genital tract upon in vivo application,
with some concentrations equal to or even slightly higher than
the EC50 that we determined in vitro and ex vivo. In this respect,
our findings might explain why HSV-2 transmission prevention
by tenofovir was not absolute but, rather, reached 51% (Abdool
Karim, 2010), although the extrapolation of active drug concen-
trations ex vivo to the situation in vivo has its limitation.
We observed tenofovir activity against both laboratory and
clinical HSV-1 and HSV-2 isolates (wild-type and drug-resistant
thymidine kinase-deficient virus strains) in: (1) HEL cell fibro-
blasts, (2) primary macrophages and keratinocytes, (3) organo-
typic epithelial raft cultures, (4) human lymphoid and cervicova-
ginal tissues ex vivo, and (5) HSV-1- and HSV-2-infected mice.
The most pronounced antiherpetic activity of tenofovir was
observed in macrophages. Although HSV targets in tissues are
still poorly understood and it is not knownwhether macrophages
are important HSV targets in vivo, it seems that both HIV-1 and
HSV-2 can infect macrophages. HIV-1 has been recovered
frequently from genital herpes lesions in coinfected individuals
(Schacker et al., 1998). Cells of the M/M lineage reside in genital
mucosal tissues and are thought to be reservoirs of HIV-1 in the
genital tract (Lehner et al., 1991; Spira et al., 1996). Moreover,
there is evidence that HSV infection can also stimulate macro-
phages in vitro and induce HIV-1 replication in these cells (Mor-
iuchi et al., 2000). The observed marked inhibitory activity of te-
nofovir against HSV-2 in M/M cultures is likely due to the low
endogenous dNTP pools (Perno et al., 1996) and/or to low
HSV-2 replication in this cell type. Low endogenous dNTP pools
give tenofovir a competitive advantage to interact with the
herpetic DNA polymerase activity. Furthermore, we deciphered386 Cell Host & Microbe 10, 379–389, October 20, 2011 ª2011 Elsevthat the molecular mechanism of the tenofovir antiherpetic
activity: tenofovir diphosphate, to which tenofovir converted in
various human cell types, efficiently inhibits HSV DNA poly-
merase. Concentrations of this compound in the cells were in
the range of concentrations that inhibited HSV DNA polymerase
in a cell-free system.
Thus, our findings provide a direct explanation for the dual anti-
HIV/HSV activity reported by the CAPRISA 004 microbicide trial
(Abdool Karim et al., 2010; Cates, 2010). Indeed, in our experi-
ments, tenofovir suppressed HSV activity at concentrations of
approximately  10–200 mg/ml, which are in the range of the
drug concentrations reached in cervicovaginal fluid upon appli-
cation of 1% tenofovir gel (Schwartz et al., Abstract LBPEC03,
5th IAS, Cape Town, South Africa, 19-22 July 2009). Such teno-
fovir concentrations were not found to be toxic in our cell models,
in agreement with previous findings that a 1% tenofovir gel does
not affect either PBMCs or epithelial cells (Rohan et al., 2010).
Neither was any toxicity observed in the CAPRISA 004 trial.
Shortly after the publication of the CAPRISA 004 results, oral
Truvada, a combination of tenofovir disoproxil fumarate (TDF)
and emtricitabine, was reported to provide a 44% reduction in
the incidence of HIV in case of pre-exposure chemoprophylaxis
in men who have sex with men (Grant et al., 2010). In contrast to
topical application, steady-state tenofovir concentrations in the
genital tract following oral administration (300 mg/day) have
been shown to be 100ng/ml (Dumondet al., 2007). Although te-
nofovir concentrations generated during oral drug administration
may be sufficient for an effective systemic inhibition of HIV infec-
tion, they are substantially lower than those necessary to inhibit
the replication of herpesviruses. Accordingly, prevention of
HSV-2 acquisition was not reported in this trial. Also, no epidemi-
ological evidence has emerged of concomitantly decreased inci-
dence of HSV-2 infection in HIV-infected individuals treated with
systemic (oral) tenofovir DF. In fact, it was very recently reported
that oral tenofovir administered as part of combination antiretrovi-
ral therapy had no suppressive effect on HSV shedding in HIV/
HSV-coinfected asymptomatic adults (Tan et al., 2011). Also,
another recent report showed that daily oral tenofovir DF (in cofor-
mulation with FTC) did not reduce HSV-2 acquisition among
high-riskmenwhohavesexwithmen, likelybecauseTDFconcen-
trations in the rectal orpenile tissues insufficientlydecreaseacqui-
sition of HSV-2 infection (Lamaet al., Abstracts of the 18th Confer-
ence on Retroviruses and Opportunistic Infections, Boston,
Massachusetts, USA, 27 February-2 March 2011, # 1002).
Surprisingly, in contrast to the partial prevention of HIV acqui-
sition upon topical intravaginal administration of a 1% tenofovir
gel (Abdool Karim et al., 2010) and upon oral drug administration
inmen who have sex withmen (Grant et al., 2010), the FEM-PrEP
HIV prevention study with oral Truvada has been stopped due to
inability to determine effectiveness (http://sciencespeaksblog.org/
2011/04/18/fem-prep-hiv-prevention-study-halted-due-to-futility/).
No significant differences on the number of new HIV infections
were observed between placebo- and drug-treated individuals.
Although the reasons for this apparent discrepancy have not
been revealed yet, it should be clear that the oral administration
of tenofovir does not affect the rate of HSV-2 sexual transmission
(Tan et al., 2011), in contrast with the topical drug administration.
This conclusion will be further tested in the ongoing VOICE clin-
ical trial, which has both topical and systemic application arms.ier Inc.
Cell Host & Microbe
Direct Antiherpetic Activity of TenofovirAlthough we have consistently demonstrated the antiherpetic
activity of tenofovir in different systems, its potency is predict-
ably lower than that of specific antiherpetic drugs like acyclovir.
Indeed, tenofovir was designed to suppress HIV-1, not herpesvi-
ruses. However, when the drug was tested upon oral administra-
tion, the high concentrations achieved with topical application
were not considered. With the CAPRISA 004 trial, it became
clear that these concentrations have now become clinically rele-
vant and have been shown to suppress not only HIV-1, but also
HSV. Here, we showed that tenofovir affects HSV directly, rather
than through a complex, indirect mechanism. Together, these
findings argue that ‘‘marginal’’ antiviral activities of a variety of
existing drugs should be revisited in light of possibly missed anti-
viral activities in topical applications as new microbicides with
dual or multiple antiviral properties. In this respect, it would be
important to consider acyclovir prodrugs as potential microbici-
dal candidates. Indeed, acyclovir, which traditionally has been
regarded only as a potent antiherpesvirus inhibitor, has recently
been shown to have dual antiviral properties: in lymphoid and
cervicovaginal tissues coinfected with herpesviruses, it effi-
ciently inhibits HIV-1 as well (Lisco et al., 2008).
Thus, in this respect, like tenofovir, acyclovir prodrugs can
become potential dual-targeted microbicides. Importantly, it
has been shown that prodrugs of phosphorylated acyclovir
that bypass the requirement of the presence of herpesvirus for
drug activation (phosphorylation) release the activated form of
acyclovir intracellularly and are endowed with both antiherpetic
and anti-HIV activity (Derudas et al., 2009; Vanpouille et al.,
2010). However, findings on the antiviral activities of various
compounds in ex vivomodels (and even in ex vivo human tissues
that closely reflect human tissues in vivo) have their limitations
and should be verified in clinical trials.
In conclusion, our data provide a plausible explanation for the
unexpected antiherpetic activity of 1% tenofovir gel observed
among treated African women participating in the CAPRISA
004 trial. Furthermore, our results provide specific consider-
ations for designing new microbicides with a dual antiviral effect
and indicate that topical creams, rather than oral administration
of anti-HIV compounds, particularly tenofovir and its derivatives,
may be efficient in preventing transmission of HIV-1 and its
copathogens.
EXPERIMENTAL PROCEDURES
Cells
Human embryonic lung HEL-299 fibroblasts were obtained from the American
Type Culture Collection (ATCC). Primary human keratinocytes (PHKs) were
isolated from neonatal foreskins and cultured as previously described (Andrei
et al., 2005). TZM-Bl cells (Montefiori, 2009) were kindly provided by Dr. G. Van
Ham, Institute for Tropical Medicine (ITG), Antwerp, Belgium.
Viruses
The HSV-1 strains KOS and F and the HSV-2 strains G and MS were used as
reference herpesviruses. Several HSV-1 wild-type (RV-6, RV-132, RV-134,
C559143, RV-174, RV-175), HSV-1 thymidine kinase-deficient (TK) (RV-36,
RV-117, 328058, RV-179), HSV-2 wild-type (RV-24, RV-124, NA, PB, NS,
HSV-47) and HSV-2 TK (RV-101, RV-129, BA 19026589, LU C557672,
HSV-44, RV-184, RV-185) clinical strains isolated from virus-infected individ-
uals in Belgium were used. They were obtained as part of a translational
research program (http://www.regavir.org) granted by the Belgian Ministry of
Health as part of the National Cancer Plan for the diagnosis of drug resistanceCell Hostin herpesviruses. All viruses were obtained and used as approved by the
Belgian equivalent of IRB (Departement Leefmilieu, Natuur en Energie,
protocol SBB 219 2011/0011, and the Biosafety Committee at K.U. Leuven).
The genotype of the TK virus strains is included in Table 1. HIV-1 strains
IIIB and Ba-L were provided by Drs. R.C. Gallo and M. Popovic (at that time
at the National Institutes of Health, Bethesda, MD).
Compounds
The sources of compounds were acyclovir (ACV, 9-2-hydroxyethoxymethyl,
GlaxoSmithKline, Stevenage, UK; (S)-HPMPC (cidofovir, CDV, (S)-1-(3-
hydroxy-2-phosphonylmethoxypropyl)cytosine) PMEAPMEA, (adefovir, ADV,
9-[2-(phosphonylmethoxyethyl)adenine) and (R)-PMPA (tenofovir, TFV, (R)-9-
[2-(phosphonylmethoxypropyl)adenine]) Gilead Sciences, Foster City, CA.
Tenofovir diphosphate (TFV-DP) and acyclovir triphosphate (ACV-TP) were
obtained from Moravek Biochemicals, Brea, CA.
Radiochemicals
[3H]tenofovir (radiospecificity: 15 Ci/mmol) and [2,8-3H]dATP (radiospecificity:
153 Ci/mmol) were obtained from Moravek Biochemicals, Brea, CA.
HSV Cytopathic Effect (CPE) Measurements
The HSV-induced cytopathic effect (CPE) was evaluated in HSV-infected HEL
and PHK cultures as described (Andrei et al., 2000, 2005). Briefly, cells were
infected with each viral strain at 100 TCID50 (1 TCID50 being the 50% tissue
culture infective dose, or virus dose, required to infect 50% of the number of
virus-exposed cell cultures) and cultured in 96-well microtiter plates for
3 days in the presence of several concentrations of the test compounds. After
the incubation period at 37C in aCO2-controlled (5%) humidified atmosphere,
CPE was visually assessed, and the 50% effective concentration (EC50,
compound concentration required to reduce viral CPE by 50%) was
determined.
Cytotoxicity Assays
Cytostatic activity measurements were based on the inhibition of cell growth.
HEL cells and PHKs were seeded at 5 3 103 cells/well into 96-well microtiter
plates and allowed to proliferate for 24 hr. Then, medium containing different
concentrations of the test compounds was added. After 3 days of incubation
at 37C, the cell number was determinedwith a Coulter counter. The cytostatic
concentration was calculated as the CC50, or the compound concentration
required reducing cell proliferation by 50% relative to the number of cells in
the untreated controls. CC50 values were estimated from graphic plots of
the number of cells (percentage of control) as a function of the concentration
of the test compounds. Alternatively, cytotoxicity of the test compounds
was measured on day 3 after exposure of the test compounds and expressed
as the minimum cytotoxic concentration (MCC), or the compound concentra-
tion that caused a microscopically detectable alteration of cell morphology.
Cytotoxicity of tenofovir in epithelial TZM-Bl cell cultures has also been
measured by the MTT method. Confluent cell cultures in 96-well microtiter
plates were exposed to different concentrations of tenofovir for 3–4 days, after
which the cell cultures were exposed to the MTT tetrazolium dye. Viable cells
convert the compound to a blue formazan derivative, which can be quantified
by optical density measurements (Pannecouque et al., 2008).
Virus Yield Reduction Assays
These assays were carried out in HEL cell monolayers at different times post-
infection. Cells were grown in 24-well microtiter plates and infected with two
HSV-2 clinical isolates (NS and RV-124) at the indicatedmultiplicity of infection
(moi). After 2 hr at 37C, the cells were washed and the medium containing
different concentrations of tenofovir (in duplicate) was added. Following 24,
48, and 72 hr of incubation, the viruses were released by freeze thawing and
then titrated by plaque assay in HEL cells. The EC90 and EC99 are defined as
the drug concentrations causing a 90%or 99% reduction, respectively, in virus
production as measured following viral titration by plaque assay.
Herpesvirus Infection of Primary Monocyte/Macrophage
Cell Cultures
Human peripheral blood mononuclear cells (PBMCs) obtained from the
blood of healthy seronegative donors were seeded into 48-well plates& Microbe 10, 379–389, October 20, 2011 ª2011 Elsevier Inc. 387
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onto plastic and estimated to be 105/well. They were cultured for an additional
3 days and infected with HSV-2 (100 TCID50) in the absence or presence of
tenofovir. The drug was maintained throughout the experiment. CPE for
macrophages was evaluated at day 6 postinfection. The amount of infectious
virus in the supernatants was determined by a classical cytopathogenicity
(CPE) reduction assay and by a plaque-forming units (PFU) reduction assay
on Vero cell cultures (Brand et al., 2001). Details on themonocyte/macrophage
preparation and antiviral activity measurements are provided in the Supple-
mental Information.
Organotypic Epithelial Raft Cultures
Primary human keratinocyte (PHK) cells were seeded on the top of collagen
gels in 24-well microtiter plates and maintained in a submerged state for
24–48 hr. The collagen rafts were then raised and placed into stainless steel
grids at the interface between air and liquid culture medium. The epithelial
cells were allowed to stratify as described (Andrei et al., 2005). Rafts were
infected with 5,000 PFU of HSV-1KOS or HSV-2G at 10 days after lifting and
treated with tenofovir. Five days later, one series of rafts was fixed in 10%buff-
ered formalin, embedded in paraffin, and stained with hematoxylin and eosin
for histological evaluation. Another series of rafts was used to quantify virus
production. For that purpose, each raft was frozen in 3 ml phosphate buffered
saline (PBS) and thawed to release the virus from the infected epithelium.
Supernatants were clarified by centrifugation at 1,800 rpm and titrated by
plaque assay in HEL cells as follows: 10-fold serially diluted samples were
added to confluent monolayers of HEL cells in 96-well plates (100 ml/well and
6 wells per dilution). The cultures were incubated at 37C for 2 days, and the
numbers of plaques were counted. Titers were calculated as PFU per milliliter
of virus suspension. Virus productionper raftwas thencalculated. Two rafts per
drug concentration were used to determine the effects of the compounds on
virus yield.
Human Ex Vivo Tissues
Human tonsillar tissues were obtained from patients undergoing routine tonsil-
lectomy at the Children’s National Medical Center (Washington, DC) under
Institutional Review Board (IRB)-approved protocol. Cervical tissues were ob-
tained through the National Disease Research Interchange (NDRI, Philadel-
phia, PA). Tissues were dissected into about 23 23 2 mm blocks and placed
onto collagen sponge gels in culture medium at the air-liquid interface as
described earlier (Grivel and Margolis, 2009). For tonsillar tissue for each
experimental condition, 27 tissue blocks (9 blocks/well filled with 3 ml of
medium) were inoculated with HSV-1 (strain F) or HSV-2 (strains G and MS).
In coinfection experiments, tissue blocks were sequentially infected with
HSV-2G and HIV-1LAI. (obtained from the Rush University Virology Quality
Assurance Laboratory, Chicago, IL). For cervicovaginal tissue, 16 blocks
were infected by immersion in HSV-2G-containing medium and maintained
on the gelfoam rafts. Tenofovir was added to the culture medium 12 hr prior
to viral infection and replenished at each culture medium change. HSV replica-
tion was evaluated by the release of viral DNA into the culture medium as
measured by quantitative real-time PCR (Lisco et al., 2008). HIV-1 replication
was evaluated by the release of p24 capsid antigen using a bead-based assay
(Biancotto et al., 2009).
In Vivo Antiviral Activity of HSV-1- and HSV-2-Infected Mice
Female adult NMRI athymic nude mice or hairless mice (weighing 20 g and
 4 weeks of age) were scarified on the lumbosacral area over a surface of
about 1 cm2 with 5 3 103 PFU of HSV-1KOS or 5 3 10
2 of HSV-2G.
Topical formulations of tenofovir, adefovir, and cidofovir (1% in 100%
DMSO to ascertain prolonged local exposure to the drugs or in a gel identical
to that used in the CAPRISA 004 trial) were applied topically twice a day for
5 days, starting 1–2 hr postinfection. In each experiment, a group of animals
was treated with a placebo formulation that contained exactly the same
vehicle but without drug. All animal procedures were approved by the K.U.
Leuven Animal Care Committee. Development of lesions and mortality were
recorded over a 1 month period. Survival rates were estimated according to
the Kaplan-Meier method and compared using the log-rank test (Mantel-
Cox) using GraphPad Prism.388 Cell Host & Microbe 10, 379–389, October 20, 2011 ª2011 ElsevMetabolism of Tenofovir in Lymphocyte, Fibroblast, and Epithelial
Cell Cultures
Metabolism of radiolabeled tenofovir was monitored as follows: CEM, HEL, or
TZM-Bl cells were seeded at 4 3 105, 5.1 3 105 and 17 3 105 cells/ml,
respectively, in 5 ml culture flasks (25 cm2) and incubated with 0.6 mg/ml
[2,8-3H]tenofovir (10 mCi/flask) for 24 hr. Cells were collected and washed by
centrifugation, and [3H]tenofovir and its metabolites in the culture superna-
tants were quantified by HPLC analysis (Balzarini et al., 1991). In a second
set of experiments, tenofovir-diphosphate levels were measured in TZM-Bl
cell cultures that were exposed to 0.6, 6, 60, and 600 mg/ml tenofovir for 24 hr.
HSV-1 DNA Polymerase and HIV-1 Reverse-Transcriptase Assay
The reactionmixture (40ml) for theHSV-1DNApolymerase andHIV-1RT assays
contained 4 ml Premix (200mMTris.HCl [pH 7.5]; 2mMDTT; 30mMMgCl2), 4 ml
BSA (5 mg/ml), 1.6 ml activated calf thymus DNA (1.25 mg/ml), 0.8 ml dCTP
(5 mM), 0.8 ml dTTP (5 mM), 0.8 ml dGTP (5 mM), 2 ml radiolabeled [3H]dATP
(1 mCi/ml) (3.2 mM), 18 ml H2O, and 4 ml tenofovir-DP at different concentrations
(i.e., 200, 20, 2, or 0.2 mM). In the HSV DNA polymerase assays, the inhibitory
effect of tenofovir-diphosphate on herpesvirus DNA polymerase-catalyzed
polymerization was also determined in the presence of radiolabeled [3H]dGTP
(1 mCi/ml) (2.8 mM), [3H]dTTP (1 mCi/ml) (1 mM), or [3H]dCTP (1 mCi/ml)
(2.5 mM) as competing dNTP in the presence of 0.8 ml (5 mM) of the other dNTPs
in the reactionmixtureasdescribedabove.The reactionwasstartedby theaddi-
tion of 4 ml recombinant HSV-1 DNA polymerase (kindly provided by M.W.
Wathen [Pfizer, Kalamazoo, MI]) or recombinant HIV-1 RT (in 20 mM Tris.HCl
[pH 8.0]; 1 mMDTT; 0.1 mM EDTA; 0.2M NaCl; or 40% glycerol), and the reac-
tionmixturewas incubated for 60min (HSV-1DNApolymerase) or 30min (HIV-1
RT) at 37C. Then, 1 ml ice-cold 5%TCA in 0.02MNa4P2O7.10H2Owas added
to terminate the polymerisation reaction, after which the acid-insoluble precipi-
tate (radiolabeled DNA) was captured onto Whatman glass fiber filters, type
GF/C (GE Healthcare UK Limited, Buckinghamshire, UK) and further washed
with 5% TCA and ethanol to remove free radiolabeled dATP. Radioactivity
was determined in a Perkin Elmer Tri-Carb 2810 TR liquid scintillation counter.
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The GenBank accession number for the viral TK sequences reported in this
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The GenBank accession number for the viral TK sequences reported in this
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